Why is Moderna (MRNA) Stock Trending After Hours?
Key takeaways
- Moderna’s stock surged after ESMO abstract acceptance, hinting at promising oncology data that could lift the company’s valuation.
- 6.98% jump to $194.82
- $194.99 after‑hours
- 52‑week high $195.71
What happened
Moderna shares jumped 6.98% to close at $194.82 after the company announced that three abstracts on its investigational mRNA‑based neoantigen therapy, intismeran, were accepted for presentation at the European Society for Medical Oncology Congress 2026 in Madrid.
Why it matters
The acceptance signals that early clinical data for intismeran are compelling enough for a major oncology conference, boosting investor confidence in Moderna’s oncology pipeline and potentially raising the company’s valuation.
Short-term and longer-term
Short-term. Moderna’s shares surged 6.98% to $194.82, bringing the stock to within $0.93 of its 52‑week high of $195.71.
Longer-term. The acceptance of three abstracts signals that Moderna’s intismeran therapy is progressing through early clinical stages, potentially expanding its oncology portfolio beyond COVID‑19 vaccines.